Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Retained Earnings (2017 - 2022)

Historic Retained Earnings for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to -$417.8 million.

  • Iterum Therapeutics' Retained Earnings fell 1162.83% to -$417.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$417.8 million, marking a year-over-year decrease of 1162.83%. This contributed to the annual value of -$378.5 million for FY2021, which is 3191.17% down from last year.
  • Iterum Therapeutics' Retained Earnings amounted to -$417.8 million in Q3 2022, which was down 1162.83% from -$388.7 million recorded in Q2 2022.
  • In the past 5 years, Iterum Therapeutics' Retained Earnings registered a high of -$82.6 million during Q2 2018, and its lowest value of -$417.8 million during Q3 2022.
  • Moreover, its 5-year median value for Retained Earnings was -$269.6 million (2020), whereas its average is -$271.3 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 14077.5% in 2018, then surged by 99.96% in 2022.
  • Quarter analysis of 5 years shows Iterum Therapeutics' Retained Earnings stood at -$131.8 million in 2018, then tumbled by 78.25% to -$234.9 million in 2019, then decreased by 22.14% to -$286.9 million in 2020, then tumbled by 31.91% to -$378.5 million in 2021, then fell by 10.39% to -$417.8 million in 2022.
  • Its last three reported values are -$417.8 million in Q3 2022, -$388.7 million for Q2 2022, and -$382.0 million during Q1 2022.